Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SABRE: Camrelizumab + Apatinib + SBRT/LDRT in NSCLC
NCT04878107Phase 2Unknown
- Sponsor
- Wuhan University
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Wuhan University. Status: unknown.
02
Drugs
camrelizumabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04878107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04878107.